BearingPoint Study Unveils Three Steps for Enhanced Welfare Services
1.8.2023 09:55:00 EEST | Business Wire | Press release
Management and technology consultancy BearingPoint has released its latest study, “Digital delivery holds the key for enabling better welfare services,” which examines the digital maturity of social welfare services across ten countries in Europe, North America, and Asia-Pacific. The study assesses the state of various social welfare programs, focusing on core industry digital dimensions and social protection categories, and highlights how governments are leveraging digital transformation to meet evolving socio-economic needs and introducing innovative solutions. The study identifies three crucial steps for government ministries and agencies responsible for social welfare services to enhance well-being outcomes for citizens:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230801342246/en/
• Reorient social welfare services around citizen segments and specific needs
• Rethink how to deliver true change and transformation in the delivery of services
• Realize tangible social and economic benefits for both public servants and citizens
This study explores why these actions are necessary, outlining what government leaders must do now and the anticipated benefits and outcomes.
Andrew Montgomery, Global Leader Government and Public Sector at BearingPoint, states: “Social welfare services form a significant part of annual expenditure for all governments, both in terms of citizen payments and service delivery costs. Our research and client experience highlights how digital and innovative technologies can improve the alignment of services with citizen needs, enable quicker responses to changing socio-economic conditions and ensure effective allocation of social welfare budgets.”
The global social welfare digital services leaders
As social welfare is a vast domain with many evolving digital developments, a simple, single-dimension maturity model would not provide any meaningful insight. Therefore, the study’s approach was multi-dimensional, examining the global digital service maturity of social welfare benefits across four digital dimensions and six social welfare categories. Of the ten countries assessed for their achievements in digitalizing access to social welfare services, the research shows that countries like Singapore, France, and Canada are typically at a higher level of digital maturity than others and offer leading practice examples. Singapore was the most digitally mature globally.
Countries were assessed on a score from 1-5 across four of the OECD’s Digital Dimensions (Digital by Design, User Driven, Government as a Platform, and Proactiveness) and the EU/EEA’s MISSOC Social Protection Categories (Unemployment, Health, Incapacity, Old-Age & Survivors, Family, and Social Assistance).
Digital by Design was the strongest dimension, with all countries optimized for digital applications and achieving an average score of 3.9 out of 5 across all categories. Proactiveness was the lowest scoring dimension across all categories, with an average aggregate score of 3.1, with opportunities identified for websites to include proactive prompts or auto-enrolment functionality.
Digital maturity in Unemployment is the strongest scoring (81%) and Incapacity (64%) the lowest in the MISSOC Social Protection Categories (Unemployment, Health, Incapacity, Old-Age & Survivors, Family, and Social Assistance).
About the study
The study examines the global digital service maturity of social welfare benefits across ten countries (Canada, Denmark, Estonia, France, Germany, Ireland, New Zealand, Norway, Singapore, and the UK), four digital dimensions, and six social welfare categories. It was based on desk-based research and validated with local contacts.
Download the study to find out more: https://www.bearingpoint.com/en/insights-events/insights/digital-strategy-for-citizens-well-being/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230801342246/en/
Contact information
Alexander Bock
Global Senior Manager Communications
Telephone: +49 89 540338029
E-Mail: alexander.bock@bearingpoint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom